Integrated profiling of human pancreatic cancer organoids reveals chromatin accessibility features associated with drug sensitivity

Xiaohan Shi, Yunguang Li, Qiuyue Yuan, Shijie Tang, Shiwei Guo, Yehan Zhang, Juan He, Xiaoyu Zhang, Ming Han, Zhuang Liu, Yiqin Zhu, Suizhi Gao, Huan Wang, Xiongfei Xu, Kailian Zheng, Wei Jing, Luonan Chen, Yong Wang, Gang Jin, Dong GaoNature Communications 2022 · DOI

TL;DR

This study tackles the challenge of understanding pancreatic cancer's complexity by integrating multi-omics data from a large biobank of patient-derived organoids. They reveal novel insights into gene regulation, identify potential non-coding drivers of cancer, and importantly, discover chromatin accessibility signatures that can predict drug sensitivity, paving the way for personalized medicine.

What Problem Does This Paper Address?

Pancreatic cancer is notoriously aggressive and difficult to treat, with current therapeutic strategies often falling short. While advances have been made in classifying pancreatic cancer based on genetics and transcriptomics, these classifications haven't consistently translated into effective, personalized treatment predictions. A key missing piece is a comprehensive understanding of how the "accessibility" of DNA (chromatin accessibility) and the intricate gene regulatory networks it controls, interact with genetic mutations and influence how tumors respond to drugs. This paper aims to fill this gap by creating a detailed map of chromatin accessibility in pancreatic cancer organoids and linking it to genomic, transcriptomic, and drug sensitivity data.

Methods

The researchers employed a multi-omics approach, integrating several key techniques:

  • Organoid Biobanking: They established a biobank of 84 patient-derived pancreatic cancer organoid (PDPCO) lines, representing a significant resource for studying this disease.
  • Whole-Genome Sequencing (WGS) & Whole-Exome Sequencing (WES): Used to identify genetic mutations, including copy number variations (CNVs) and single nucleotide variants, in both coding and non-coding regions of the genome.
  • RNA Sequencing (RNA-seq): Performed to analyze gene expression patterns and identify molecular subtypes of pancreatic cancer.
  • Assay for Transposase-Accessible Chromatin using sequencing (ATAC-seq): This is a core technique used to map regions of the genome that are "open" and thus accessible for transcription factor binding and gene regulation. This was applied to a large number of organoid lines, overcoming challenges posed by the dense stroma in primary tumors.
  • High-Throughput Drug Screening: A library of 283 epigenetic-related chemicals and 5 standard chemotherapeutic drugs were screened against the organoid lines to assess drug sensitivity.
  • Bioinformatic Integration: Sophisticated computational methods were used to integrate these diverse datasets, including principal component analysis (PCA), non-negative matrix factorization (NMF) for subtype identification, gene set enrichment analysis (GSEA), transcription factor (TF) regulon inference (using SCENIC), and correlation analyses to link ATAC-seq peaks to gene expression and drug sensitivity.

Datasets

  • Pancreatic Cancer Organoid Biobank: A newly established collection of 84 patient-derived pancreatic cancer organoid (PDPCO) lines, including 80 from exocrine tumors (PDACs, IPMNs, ACCs) and 4 from neuroendocrine tumors (NENs). Six normal pancreatic ductal organoids (NPOs) were also established.
  • TCGA Pancreatic Adenocarcinoma (PAAD) Dataset: Used for comparison and validation of genomic alterations and transcriptomic subtypes.
  • Clinical Data: Follow-up data from 39 patients whose organoids were used in the study, including information on adjuvant chemotherapy regimens and clinical outcomes.

Key Insights and Ideas

  • Chromatin Accessibility as a Key Regulator: The study strongly emphasizes that chromatin accessibility is not just a passive readout but an active player in defining cellular identity and dictating therapeutic responses in pancreatic cancer.
  • Uncovering Non-Coding Drivers: Beyond well-studied coding mutations, the research highlights the significant role of non-coding mutations, with over 500,000 identified, many of which are novel and located in regulatory regions. This opens a new avenue for understanding cancer drivers.
  • Linking Accessibility to Drug Response: The most impactful insight is the discovery that specific patterns of chromatin accessibility can serve as predictive biomarkers for drug sensitivity, offering a tangible path towards personalized treatment.
  • New Pancreatic Cancer Subtypes: The transcriptomic analysis revealed a novel "glycomet" subtype characterized by high glycometabolic activity, adding another layer to our understanding of pancreatic cancer heterogeneity.
  • Organoids as Powerful Preclinical Models: The study reinforces the utility of organoids as faithful models that recapitulate patient-specific responses to chemotherapy, both in vitro and in vivo.

Key Results

  • 84 PDPCOs Established: A comprehensive biobank of pancreatic cancer organoids was created, enabling multi-omics analysis.
  • Genomic Landscape Characterized: WGS and WES revealed genomic alterations consistent with known pancreatic cancer drivers (e.g., KRAS, TP53, SMAD4) and identified over 500,000 non-coding mutations.
  • Four Transcriptomic Subtypes Identified: Beyond established subtypes, a new "glycomet" subtype was discovered, and the "classical-progenitor" subtype showed a better prognosis.
  • Chromatin Accessibility Atlas: Over 160,000 reproducible chromatin accessibility peaks were identified across the organoid lines, providing a detailed atlas.
  • Predictive Links to Drug Sensitivity: Thousands of links between chromatin accessibility peaks and drug sensitivity were identified, with specific examples showing negative correlation with mivebresib sensitivity and positive correlation with domatinostat sensitivity.
  • Clinical Validation: Organoid sensitivity to chemotherapy was shown to correlate with patient outcomes, and this was further validated in xenograft models.

Limitations and Future Work

  • Non-coding Mutation Function: While many non-coding mutations were identified, their precise functional mechanisms remain largely unknown and require further investigation.
  • Organoid Culture Artifacts: The authors acknowledge that organoid models, while powerful, may acquire mutations or exhibit altered characteristics during extended culture.
  • Limited NEN Organoids: The study included only four NEN organoid lines, which might limit the depth of conclusions for this specific subtype.
  • Future Directions: The authors suggest that their findings provide a foundation for developing new diagnostic and therapeutic strategies, including personalized medicine approaches based on chromatin accessibility signatures and non-coding mutation analysis. Further research into the functional roles of non-coding mutations and the development of targeted therapies based on these insights are promising avenues.

Summary updated

Abstract

Abstract Chromatin accessibility plays an essential role in controlling cellular identity and the therapeutic response of human cancers. However, the chromatin accessibility landscape and gene regulatory network of pancreatic cancer are largely uncharacterized. Here, we integrate the chromatin accessibility profiles of 84 pancreatic cancer organoid lines with whole-genome sequencing data, transcriptomic sequencing data and the results of drug sensitivity analysis of 283 epigenetic-related chemicals and 5 chemotherapeutic drugs. We identify distinct transcription factors that distinguish molecular subtypes of pancreatic cancer, predict numerous chromatin accessibility peaks associated with gene regulatory networks, discover regulatory noncoding mutations with potential as cancer drivers, and reveal the chromatin accessibility signatures associated with drug sensitivity. These results not only provide the chromatin accessibility atlas of pancreatic cancer but also suggest a systematic approach to comprehensively understand the gene regulatory network of pancreatic cancer in order to advance diagnosis and potential personalized medicine applications.
BibTeX
@inproceedings{shi2022integrated,
  author = {Xiaohan Shi and Yunguang Li and Qiuyue Yuan and Shijie Tang and Shiwei Guo and Yehan Zhang and Juan He and Xiaoyu Zhang and Ming Han and Zhuang Liu and Yiqin Zhu and Suizhi Gao and Huan Wang and Xiongfei Xu and Kailian Zheng and Wei Jing and Luonan Chen and Yong Wang and Gang Jin and Dong Gao},
  title = {{Integrated profiling of human pancreatic cancer organoids reveals chromatin accessibility features associated with drug sensitivity}},
  booktitle = {Nature Communications},
  year = {2022},
  doi = {10.1038/s41467-022-29857-6},
}
Figure